Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early innate immune signatures correlate with Ad26.COV2.S vaccine durability and protective efficacy.

bioRxiv : the preprint server for biology·2026
Same author

Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine.

Science advances·2026
Same author

Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection.

bioRxiv : the preprint server for biology·2026
Same author

Displayed and encoded antigens on adenovirus vectors optimize humoral and cellular immune responses in rhesus macaques.

Journal of virology·2026
Same author

Vulnerability and Chronic Illness in Three Contemporary Romance Novels.

The Journal of medical humanities·2026
Same author

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2024.

Communicable diseases intelligence (2018)·2026

Related Experiment Video

Updated: Jun 13, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.9K

SARS-CoV-2 RBD dimers elicit response comparable to VLPs in mice.

J Love, Sergio Rodriguez-Aponte, Lisa Tostanoski

    Research Square
    |May 10, 2023
    PubMed
    Summary
    This summary is machine-generated.

    Comparing SARS-CoV-2 vaccines, dimeric and trimeric Receptor Binding Domain (RBD) protein subunits, and RBD virus-like particles (VLPs) showed similar antibody levels. Omicron RBD hetero-dimers also demonstrated comparable neutralizing activity and breadth against variants.

    More Related Videos

    Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
    07:44

    Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

    Published on: August 12, 2021

    3.2K
    Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
    08:41

    Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

    Published on: November 5, 2021

    2.8K

    Related Experiment Videos

    Last Updated: Jun 13, 2026

    Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
    12:09

    Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

    Published on: May 2, 2011

    42.9K
    Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
    07:44

    Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

    Published on: August 12, 2021

    3.2K
    Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
    08:41

    Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

    Published on: November 5, 2021

    2.8K

    Area of Science:

    • Immunology and Vaccine Development
    • Virology and Molecular Biology

    Background:

    • The SARS-CoV-2 Receptor Binding Domain (RBD) is a key target for vaccines.
    • Evaluating different vaccine formulations, including protein subunits and virus-like particles (VLPs), is crucial for effective immunization strategies.

    Conclusions:

    • Dimeric and trimeric RBD protein subunit vaccines are promising alternatives to RBD-VLPs, offering comparable immunogenicity.
    • RBD hetero-dimers, particularly against Omicron variants, show potential for broad protection.
    • These findings support the development of advanced RBD-based vaccine formulations for enhanced SARS-CoV-2 immunity.